Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors

FASEB Journal

Volumn 27, Issue 10, 2013, Pages 4279-4293

  Wissing, Michel D ^a,b,c   Mendonca, Janet ^a   Kortenhorst, Madeleine S Q ^a,c   Kaelber, Nadine S ^a   Gonzalez, Matthew ^d   Kim, Eunice ^a   Hammers, Hans ^a   Van Diest, Paul J ^c   Carducci, Michael A ^a   Kachhap, Sushant K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HDAC; Mitotic kinases; Plk1; Spindle assembly checkpoint; Synergy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; DIMETHYL SULFOXIDE; HISTONE DEACETYLASE INHIBITOR; POLO LIKE KINASE 1 INHIBITOR; POLO LIKE KINASE INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID; VOLASERTIB; VORINOSTAT; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; HYDROXAMIC ACID; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL STRUCTURE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; M PHASE CELL CYCLE CHECKPOINT; MITOSIS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PULLDOWN ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; ENZYMOLOGY; MALE; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; VALPROIC ACID;

EID: 84885146283     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-222893     Document Type: Article

References (46)

1. De Carcer, G, Manning, G., and Malumbres, M. (2011) From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 10, 2255-2262
2. Chopra, P., Sethi, G, Dastidar, S. G, and Ray, A. (2010) Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin. Invest. Drugs 19, 27-43
3. El Bahassi, M. (2011) Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions. Exp. Biol. Med. 236, 648-657
4. Takaki, T., Trenz, K, Costanzo, V., and Petronczki, M. (2008) Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr. Opin. Cell Biol. 20, 650-660
5. Schmit, T. L., Ledesma, M. C, and Ahmad, N. (2009) Modulating polo-like kinase 1 as a means for cancer chemoprevention. Pharmaceut. Res. 27, 989-998
6. Deeraksa, A, Pan, J., Sha, Y., Liu, X. D., Eissa, N. T., and Yu-Lee, L. Y (2013) Plk1 is upregulated in androgeninsensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene 32, 2973-2983
7. Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Haslinger, C, Garin-Chesa, P., and Adolf, G. R. (2009) BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin. Cancer Res. 15, 3094-3102
8. Schoffski, P. (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14, 559-570
9. Pandha, H. S., Protheroe, A, Wylie, J., Parker, C, Chambers, J., Bell, S., and Munzert, G (2008) An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC). J. Clin. Oncol. 26, 14547
10. Gandhi, L., Chu, Q. S., Stephenson, J., Johnson, B. E., Bonomi, P., Eaton, K., Fritsch, H., Munzert, G, and Socinski, M. (2009) An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC). J. Clin. Oncol. 27, 8108
11. Sebastian, M., Reck, M., Waller, C. F., Kortsik, C, Frickhofen, N., Fritsch, H., Gaschler-Markefski, B., Hanft, G, Munzert, G, and Von Pawel, J. (2010) The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J. Thorac. Oncol. 5, 1060-1067
12. Schoffski, P., Blay, J. Y, De Greve, J., Brain, E., Machiels, J. P., Wolter, P., Ray-Coquard, I., Fontaine, C, Munzert, G, Fritsch, H., Hanft, G, Aerts, C, Rapion, J., Allgeier, A, Bogaerts, J., and Lacombe, D. (2010) Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network of Core Institutes (NOCI). Eur. J. Cancer 46, 2206-2215
13. Schoffski, P., Awada, A., Dumez, H., Gil, T., Wolter, P., Taton, M., Fritsch, H., Glomb, P., and Munzert, G. (2012) A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur. J. Cancer 48, 179-186
14. Rokhlin, O. W., Glover, R. B., Guseva, N. V., Taghiyev, A. F., and Cohen, M. B. (2006) Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol. Cancer Res. 4, 113-123
15. Xu, W. S., Parmigiani, R. B., and Marks, P. A. (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26, 5541-5552
16. Kortenhorst, M. S., Zahurak, M., Shabbeer, S., Kachhap, S., Parmigiani, G., Verheul, H. M., and Carducci, M. A. (2008) A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. Clin. Cancer Res. 14, 6886-6894
17. Kachhap, S. K., Rosmus, N., Collis, S. J., Kortenhorst, M. S., Hedayati, M., Shabbeer, S., Mendonca, J., Deangelis, J., Marchionni, L., Lin, J., Hoti, N., Nortier, J. W., De Weese, T. L., Hammers, H., and Carducci, M. A. (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PloS One 5, e11208
18. Yasunaga, Y., Nakamura, K., Ewing, C. M., Isaacs, W. B., and Rhim, J. S. (2001) A novel human cell culture model for the study of familial prostate cancer. Cancer Res. 61, 5969-5973
19. Park, J. E., Li, L., Park, J., Knecht, R., Yuspa, S. H., and Lee, K. S. (2009) Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay. Proc. Natl. Acad. Sci. U. S. A. 106, 1725-1730
20. Cordoba, E. V., Arnaiz, E., De La Mata, F. J., Gomez, R., Pion, M., and Munoz-Fernandez, M. A. (2013) Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro. [E-pub ahead of print] AIDS doi: 10.1097/QAD.0b013e328361fa4a
21. Yun, S. M., Jung, K. H., Lee, H., Son, M. K., Yan, H. H., Park, B. H., Hong, S., and Hong, S. S. (2013) Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Cancer Lett. 331, 250-261
22. Chou, T. C., and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55
23. Mross, K., Frost, A., Steinbild, S., Hedbom, S., Kaiser, R., Rouyrre, N., Trommeshauser, D., Hoesl, C. E., and Munzert, G. (2008) Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 26, 5511-5517
24. Lee, K. S., Oh, D. Y., Kang, Y. H., and Park, J. E. (2008) Self-regulated mechanism of Plk1 localization to kinetochores: lessons from the Plk1-PBIP1 interaction. Cell Div. 3, 4
25. Strebhardt, K. (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat. Rev. 9, 643-660
26. Lens, S. M., Voest, E. E., and Medema, R. H. (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 10, 825-841
27. Chan, E. H., Santamaria, A., Sillje, H. H., and Nigg, E. A. (2008) Plk1 regulates mitotic Aurora A function through betaTrCP-dependent degradation of hBora. Chromosoma 117, 457-469
28. Hanisch, A., Wehner, A., Nigg, E. A., and Sillje, H. H. (2006) Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting. Mol. Biol. Cell 17, 448-459
29. Crane, R., Gadea, B., Littlepage, L., Wu, H., and Ruderman, J. V. (2004) Aurora A, meiosis and mitosis. Biol. Cell 96, 215-229
30. De Luca, M., Lavia, P., and Guarguaglini, G. (2006) A functional interplay between Aurora-A, Plk1 and TPX2 at spindle poles: Plk1 controls centrosomal localization of Aurora-A and TPX2 spindle association. Cell Cycle 5, 296-303
31. Bolanos-Garcia, V. M. (2009) Assessment of the mitotic spindle assembly checkpoint (SAC) as the target of anticancer therapies. Curr. Cancer Drug Targets 9, 131-141
32. Weaver, B. A., and Cleveland, D. W. (2005) Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8, 7-12
33. Valsasina, B., Beria, I., Alli, C., Alzani, R., Ballinari, D., Cappella, P., Caruso, M., Casolaro, A., Ciavolella, A., Cucchi, U., De Ponti, A., Felder, E., Fiorentini, F., Galvani, A., Gianellini, L. M., Giorgini, M. L., Isacchi, A., Lansen, J., Pesenti, E., Rizzi, S., Rocchetti, M., Sola, F., and Moll, J. (2012) NMS-P 937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol. Cancer Therapeut. 11, 1006-1016
34. Cazzalini, O., Scovassi, A. I., Savio, M., Stivala, L. A., and Prosperi, E. (2010) Multiple roles of the cell cycle inhibitor p21 (CDKN1A) in the DNA damage response. Mutat. Res. 704, 12-20
35. Cayrol, C., Knibiehler, M., and Ducommun, B. (1998) p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16, 311-320
36. Shabbeer, S., Kortenhorst, M. S., Kachhap, S., Galloway, N., and Carducci, M. A. (2007) Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67, 1099-1110
37. Richon, V. M., Sandhoff, T. W., Rifkind, R. A., and Marks, P. A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U. S. A. 97, 10014-10019
38. Atmaca, A., Al-Batran, S. E., Maurer, A., Neumann, A., Hentsch, B., Schwarz, S. E., Hovelmann, S., Gottlicher, M., Knuth, A., and Jager, E. (2007) Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Brit. J. Cancer 97, 177-182
39. Rubin, E. H., Agrawal, N. G., Friedman, E. J., Scott, P., Sun, L., Du, L., Ricker, J. L., Frankel, S. R., Gottesdiener, K. M., Wagner, J. A., and Iwamoto, M. (2006) A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin. Cancer Res. 12, 7039-7045
40. Weinstein, I. B., and Joe, A. K. (2006) Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. 3, 448-457
41. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737-744
42. Deininger, M. W., Goldman, J. M., Lydon, N., and Melo, J. V. (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90, 3691-3698
43. Riggs, B. L., and Hartmann, L. C. (2003) Selective estrogenreceptor modulators-mechanisms of action and application to clinical practice. N. Engl. J. Med. 348, 618-629
44. Stadler, W. M., Vaughn, D. J., Sonpavde, G., Vogelzang, N. J., Petrylak, D. P., Rosen, P. J., Lin, C., Mahoney, J. F., Modi, S. S., Lee, P., Ernstoff, M. S., Su, W., Spira, A. I., Ould, K. M., Taube, T., Vinisko, R., Schloss, C., Zhao, C., and Carducci, M. A. (2011) Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC). J. Clin. Oncol. 29, 4567
45. Deleporte, A., Dumez, H., Awada, A., Costermans, J., Berghmans, T., Ould, K. M., Juhel, N., Berge, A., Taube, T., and Schoffski, P. (2011) Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors. J. Clin. Oncol. 29, 3031
46. Prystowsky, M. B., Adomako, A., Smith, R. V., Kawachi, N., Atadja, P., Chen, Q., Schlecht, N. F., Parish, J. L., Childs, G., and Belbin, T. J. (2009) The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J. Pathol. 218, 467-477